NIEUWEGEIN, The Netherlands, January 21 /PRNewswire/ --

- Profit Forecast for 2007: Similar Operating Result (2006: EUR 42 million)

- Order Book for 2007: Sharp Rise to Approx. EUR 1.4 billion

- Final Annual Figures for 2007: 14 March 2008

Profit Forecast for 2007 Confirmed

PARIS, January 21 /PRNewswire/ --

- Consumers Can Run Stores without the Hassle of Inventory or Logistics and Discover Products within Any Category of Interest

Zlio.com, http://www.zlio.com, the world's largest emporium of specialty stores powered by users, today unveiled its UK website, offering a way for consumers to easily open their own online store for free. Consumers can populate their stores by choosing from more than one million products offered by 62 well-known UK merchants including Play and Dell, among others.

ATLANTA, January 20 /PRNewswire/ --

CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the provision and development of innovative medical devices, has released data from THE SPHERE, an 11 center, 8 country European study of uterine fibroid embolization using the Company's Embozene(TM) Microspheres. The study results were reported at the 20th Annual International Symposium on Endovascular Therapy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU001 )

ATLANTA, January 20 /PRNewswire/ --

CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the development of innovative medical devices, today announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F at the 20th Annual International Symposium on Endovascular Therapy (ISET).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU002 )

LONDON, January 19 /PRNewswire/ -- Saturday 19th January 2008 is The Great British Light Switch. In just 24 hours over two million people will receive a twin-pack of energy-saving lights free from Southern Electric.

These lights will potentially cut total CO2 emissions by over 350,000 tonnes and save Britons up to GBP20.25million per year on energy bills. Changing all the lights in the average home means households could save up to GBP600 over the bulbs' lifetime.

"The Great British Light Switch campaign is a moment in time when people can act together and make a real difference to cutting carbon emissions," commented Nic Frances, CEO, Cool nrg.

LONDON, January 18 /PRNewswire/ --

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled. During the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.